2. NF-κB
  3. Keap1-Nrf2 NF-κB
  4. Praelolide

Praelolide is a potent Nrf2 activator. Praelolide suppresses osteoclastogenesis and reactive oxygen species (ROS) production. Praelolide disrupts Keap1-Nrf2 protein-protein interactions by noncovalent binding to Keap1. Praelolide has the potential for the research of osteoclastogenic bone disease.

For research use only. We do not sell to patients.

Praelolide Chemical Structure

Praelolide Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Praelolide Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Praelolide is a potent Nrf2 activator. Praelolide suppresses osteoclastogenesis and reactive oxygen species (ROS) production. Praelolide disrupts Keap1-Nrf2 protein-protein interactions by noncovalent binding to Keap1. Praelolide has the potential for the research of osteoclastogenic bone disease[1].

In Vitro

Praelolide (compound 21) (10 µM) shows anti-osteoclastogenesis activities with the inhibitory ratio of 100% in bone marrow monocytes/macrophages (BMMs)[1].
Praelolide (1, 1.25, 5, 10 µM; 1-5 days) inhibits RANKL-induced osteoclast formation with no cytotoxicity, and inhibits bone resorption of osteoclasts and actin ring formation in BMMs[1].
Praelolide (5, 10 µM) inhibits RANKL-induced mRNA levels of NFATc1, cathepsin K, MMP-9 and TRAP in BMMs[1].
Praelolide (5, 10 µM; 6 h) increases the protein expression of Nrf2, HO-1 and NQO1, enhances the stability of Nrf2 protein[1].
Praelolide (10 µM; 0-60 min) inhibits RANKL-induced NF-κB and MAPK signaling pathways and inhibits RANKL-induced phosphorylation of ERK, p38 MAPK, IKBα, and p65 NF-kB in pre-osteoclasts[1].
Praelolide (0, 20, 50, 100 µM; 24 h) interferes the interaction between Keap1 and Nrf2 by binding to Keap1 protein in RAW264.7 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Praelolide Related Antibodies

Cell Viability Assay[1]

Cell Line: Bone marrow monocytes/macrophages (BMMs)
Concentration: 1, 2.5, 5, 10, 20, 30, 40, 50 µM
Incubation Time: 1-5 days
Result: Suppressed RANKL-induced TRAP positive osteoclasts formation in a time dependent manner, shows no effect on cell viability.

RT-PCR[1]

Cell Line: Bone marrow monocytes/macrophages (BMMs)
Concentration: 5, 10 µM
Incubation Time: 1-5 days
Result: Inhibited RANKL-induced mRNA levels of NFATc1, cathepsin K, MMP-9 and TRAP.

Western Blot Analysis[1]

Cell Line: Bone marrow monocytes/macrophages (BMMs), RAW264.7 cells
Concentration: 5, 10 µM
Incubation Time: 6 h
Result: Promoted the protein expression of Nrf2 in the nucleus and HO-1 and NQO1 in the cytoplasm, ncreased the Nrf2 stability by reducing ubiquitin degradation of Nrf2.
In Vivo

Praelolide (2, 5, 10 µM; co-treated for 6 days) rescues the bone loss of prednisone-induced zebrafish[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Zebrafish larvae at the age of 3 dpf (day-post-fertilization)[1]
Dosage: 2, 5, 10 µM
Administration: Co-treated for 6 days
Result: Remarkably increased the amount of bone mineralization in prednisolone-treated zebrafish larvae especially at the concentration of 5 μM which even excelled 10 μM praelolide-treated group.
Molecular Weight

599.02

Formula

C28H35ClO12
SMILES

[H][C@@]1([C@H](OC(C)=O)[C@](O2)([C@H]3C)[C@@H](OC3=O)[C@H]4Cl)[C@@]([C@@H](OC(C)=O)CC[C@@]15OC5)(C)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2C4=C
Structure Classification
Initial Source

Junceella juncea
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Praelolide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PraelolideKeap1-Nrf2NF-κBNuclear factor-κBNuclear factor-kappaBanti-osteoclastogenesisROSosteoclastogenic bone diseaseMAPKzebrafishInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Praelolide
Cat. No.:
HY-N10659
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.